Russell’s viper (Daboia russelii) envenomation is a major public health problem in South and Southeast Asia, often resulting in life-threatening complications such as acute kidney injury (AKI), disseminated intravascular coagulation (DIC), and shock. Serum lactate dehydrogenase (LDH), an accessible and cost- effective biochemical marker, has been proposed as a surrogate indicator of tissue injury, haemolysis, and severity of systemic envenomation. This review explores the role of LDH in the context of Russell's viper bite, examining the pathophysiological basis of envenomation and its complications, the mechanism of LDH elevation, and clinical studies correlating LDH levels with severity and outcomes. The findings suggest that elevated LDH may assist in early recognition of severe envenomation, guide timely interventions, and serve as a valuable adjunct to clinical and laboratory assessment in resource-limited settings.

Russell’s viper (Daboia russelii) envenomation is a major cause of morbidity and mortality in Myanmar, often complicated by acute kidney injury (AKI), disseminated intravascular coagulation (DIC), and shock. Serum lactate dehydrogenase (LDH), a marker of tissue injury and hemolysis, shows promise as an indicator of envenomation severity. The objective of this study is to determine the association between serum LDH levels and clinical outcomes in patients with Russell’s viper envenomation. A hospital-based cross-sectional study was conducted at Mandalay General Hospital, Myanmar, from January to December 2018. Patients admitted within 72 hours of confirmed Russell’s viper bite were included. Serum LDH was measured 18–72 hours after the bite, and outcomes recorded included AKI, DIC, shock, and mortality. Statistical analysis was performed using t-tests and one-way ANOVA, with p < 0.05 considered significant.

There has been significant magnitude of problems of diabetes in Myanmar, according to the estimates of International Diabetes Federation (IDF) and the recent National Survey on the prevalence of diabetes. There has been a wide gap of equity between the urban and rural healthcare delivery for diabetes. Myanmar Diabetes Care Model (MMDCM) aims to deliver equitable diabetes care throughout the country, to stem the tide of rising burden of diabetes and also to facilitate to achieve the targets of the Global Action Plan for the Prevention and Control of NCDs (2013-2020). It is aimed to deliver standard of care for diabetes through the health system strengthening at all level. MMDCM was developed based on the available health system, resources and the country's need. Implementation for the model was also discussed.